抗骨誘導(dǎo)因子(OGN)多克隆抗體
Anti-Osteoglycin (OGN) Polyclonal Antibody
OIF; SLRR3A; Mimecan Proteoglycan; Osteoinductive Factor
- 編號(hào)FAC688Ra01
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 效價(jià)-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 激發(fā)波長(zhǎng)
- 單次使用量
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 且適物種Homo sapiens (Human，人)
- 應(yīng)用FCM
- 下載英文說明書 中文說明書
- 規(guī)格25test50test100test200test500test
- 價(jià)格暫無報(bào)價(jià)暫無報(bào)價(jià)暫無報(bào)價(jià)暫無報(bào)價(jià)暫無報(bào)價(jià)
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Human HepG2 cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20μg/ml rabbit Anti-rat OGN Polyclonal Antibody (Catalog FAC688Ra01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1μg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
用法
Flow cytometry: 20μg/ml;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過一年。避免反復(fù)凍融。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC688Ra01 | 骨誘導(dǎo)因子(OGN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC688Ra01 | 骨誘導(dǎo)因子(OGN)多克隆抗體 | WB |
| FAC688Ra01 | 抗骨誘導(dǎo)因子(OGN)多克隆抗體 | FCM |
| LAC688Ra71 | 骨誘導(dǎo)因子(OGN)多克隆抗體(生物素標(biāo)記) | WB |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Bone. | Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus.[pubmed:27836731] |
| Tohoku journal of experimental medicine | Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease.[pubmed:28824047] |
| Molecular Metabolism | Osteoglycin, a novel coordinator of bone and glucose homeostasis[Pubmed:29799418] |
| Journal of Experimental &?Clinical?Cancer?Research | Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway[Pubmed:29499765] |
| Journal of Human Hypertension | Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients[Pubmed:29867136] |
| Cell?Reports | Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue[Pubmed: 30332637] |
| J Clin Endocrinol Metab | Osteoglycin across the adult lifespan[34850904] |